Care Health Insurance (Religare) Unlisted Shares

Care Health Insurance (Religare) Unlisted Shares

Religare Health Insurance Ordered To Pay ₹8.56 Lakh For Denied Chemotherapy Bills By Consumer Commission

Free pass journal

2 min read

Insurance Commission Orders Religare to Pay Rs 8.56 Lakh for Chemotherapy.

Expert Analysis:

  • Commission Reprimands Religare for Chemotherapy Denia: The Suburban Mumbai Additional District Consumer Dispute Redressal Commission (DCDRC) has reprimanded Religare Health Care Insurance for refusing to cover chemotherapy expenses, citing the consumer's failure to disclose her medical conditions of hyper-lipidemia and allergic asthma.

  • Commission's Financial Orders Against Insurance Firm: The commission has ordered the insurance firm to pay Rs 8,56,592 for the complainant’s medical bills, along with 9% interest from November 2014. Additionally, they must refund the policy amount of Rs 24,875, accompanied by additional amounts of Rs 25,000 and Rs 15,000 towards the complainant’s mental agony and litigation charges, accordingly.

  • Medical Treatment and Insurance Claim Submission: Hitesh Sheth from Ghatkopar bought a Rs 24,875 mediclaim policy with Religare Health Care starting November 30, 2013. In April 2014, his wife Anjana underwent surgery and chemotherapy at Somaiya Ayurvihar Asian Institute of Oncology for breast conditions. They submitted the medical bills to the insurer for reimbursement.

  • Claim Rejection: The insurance firm cited undisclosed hyper-lipidemia and allergic asthma as grounds to reject Anjana's claim for chemotherapy expenses.

  • Firm's Response on Medical History: The forum, upon reviewing the evidence, requested the insurance firm to respond. The company stated, "Medical documents show that the complainant's wife had known hyper-lipidemia and allergic asthma since 2005, which were not disclosed in the policy proposal. Therefore, the claim was rejected based on policy terms."

  • Commission Rejects Company's Defense: The commission, however, rejected the company’s say and asked them to pay for the complainant’s medical expenses.

Takeaways
  • Transparency in Communication:

    • Care Health Insurance (Religare) needs to ensure transparent communication and fair assessment in claims processing.

  • Evidence-based Decision Making:

    • Insurers should substantiate claim denials with clear evidence, especially regarding pre-existing conditions.

  • Thorough Evaluation:

    • Priority should be given to thorough evaluation of medical claims to uphold fairness and customer trust.

  • Compliance and Trust:

    • Upholding fairness in claims processing is crucial for maintaining customer trust and regulatory compliance.

Invest in the Future
Act now and capitalize on the potential growth of this unlisted share

Precize Daily Pulse

The latest news in the world of Unlisted Shares, summarised by our experts.

The next generation of asset classes in India

Resources

Our Office

Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093

Find us on Google

support@precize.in

+91 7738336457

All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.

The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.

Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.

The website will be updated regularly.

Copyright © 2026 - Precize - All Rights Reserved